Provention Bio, Inc.
PRVBNASDAQHealthcare
$24.98
+$0.00(+0.00%)
Market Cap$2.4B
P/E Ratio—
52W High$25.0
52W Low$3.185
Provention Bio, Inc.（PRVB）· 现金流量表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · PRVB · 截至 2026-06-10
财务报表
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2022-12 | 2021-12 | 2020-12 | 2019-12 | 2018-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($113.56M) | ($114.43M) | ($98.58M) | ($43.28M) | ($26.48M) |
| Depreciation & Amort. | $1.23M | $0.39M | $0.03M | ($0.02M) | $0.00M |
| Stock-Based Comp. | $19.03M | $11.84M | $13.22M | $2.84M | $1.14M |
| Change in Working Capital | $17.94M | $6.32M | $8.72M | $4.39M | ($1.80M) |
| Net Cash from Operations | ($75.41M) | ($95.39M) | ($76.34M) | ($36.06M) | ($22.64M) |
| Investing Activities | |||||
| Capital Expenditure | ($0.80M) | ($0.96M) | ($1.11M) | $0.00M | $0.00M |
| Purchases of Investments | ($103.08M) | ($55.28M) | ($28.71M) | ($46.25M) | $0.00M |
| Sales of Investments | $30.75M | $25.15M | $55.00M | $0.00M | $0.00M |
| Net Cash from Investing | ($88.13M) | ($31.10M) | $25.17M | ($46.25M) | $0.00M |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Cash from Financing | $129.38M | $102.38M | $114.29M | $62.94M | $59.35M |
| Free Cash Flow | |||||
| Free Cash Flow | ($76.20M) | ($96.35M) | ($77.45M) | ($36.06M) | ($22.64M) |
| FCF Margin %(computed) | -590.95% | — | — | — | — |
数据来源：Financial Modeling Prep · 最后更新：2026-06-10 · USD · M
深入了解Provention Bio, Inc.
关于Provention Bio, Inc.（PRVB）现金流量表
Provention Bio, Inc. 2022财年经营活动现金流($0.08B)，自由现金流($0.08B)（FCF利润率-590.95%），资本支出($0.00B)。
常见问题
PRVB · 4 问Provention Bio, Inc. 2022财年自由现金流($0.08B)，同比up20.9%。
PRVB free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10